Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
New guidelines around the use of nonhormonal therapy for hot flashes — or vasomotor symptoms— due to menopause have been released by the North American Menopause Society. Cognitive behavioural therapy has been demonstrated to improve sleep, mood and bother of vasomotor symptoms, and in some studies to reduce the frequency of vasomotor symptoms 4. Hypnosis. Hypnosis has been shown to reduce vasomotor symptoms severity and frequency, and has been useful for reducing anxiety and improving sleep 5. Abstract. Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as many as 68.5% of women as a result of menopause. While the median duration of these symptoms is 4 years, approximately 10% of women continue to experience VMS as many as 12 years after their final menstrual period. Vasomotor symptoms are common among postmenopausal women and patients receiving hormone deprivation therapies, and emerging studies are exploring gabapentin’s and pregabalin’s effects as nonhormonal treatment options. Clinical guidelines from American, European, and Asian countries have suggested these 2 drugs as nonhormonal treatment options for vasomotor symptoms. 6–9, 14 Given the promising benefits of gabapentin, attempts have been made to summarize its effectiveness, 15–18 but previously published meta-analyses focused just on the whole gamut of nonhormonal treatment modalities, with a limited Gabapentin (Neurontin) has shown efficacy in relieving vasomotor symptoms and is used as off-label for this indication. A new extended-release formulation of gabapentin has also shown efficacy in treating hot flashes and improving sleep quality with possibly fewer side effects than regular gabapentin. Gabapentin is a drug that doctors sometimes prescribe off-label to reduce hot flashes during menopause. Instead of affecting hormones, experts think it may act on the hypothalamus, the part of Objective: Gabapentin is used to treat vasomotor symptoms (VMS) in postmenopausal women with contraindications to hormonal therapy or who prefer alternatives. We investigated the efficacy and tolerability of gabapentin for treating menopausal hot flushes via a meta-analysis. which is theory based can have an impact on both vasomotor symptom perception and control and reduction in stress and wellbeing, sleep problems and vasomotor symptomatology. There are two-way interactions between mood and vasomotor symptoms with 10% of women more likely to have depressed mood during menopause. Favorable effects of gabapentin in relieving vasomotor symptoms were observed, compared with controls, but were less effective than those of estrogen. Evidence supporting the therapeutic effect of pregabalin is still lacking. In a large meta-analysis by Shan et al., the efficacy and safety of gabapentin and pregabalin were evaluated in women suffering from vasomotor symptoms. A total of 19 randomized controlled trials and two crossover studies were included in the analysis, totalling nearly 3,500 women. Gabapentin may be a beneficial therapeutic option for managing vasomotor symptoms (VMS) in postmenopausal women who are unable to take hormonal therapy (HT) or prefer an alternative treatment The median age of menopause in North America is 51 years. There is an array of menopausal symptoms; however, vasomotor and vaginal symptoms are the most closely related to hormonal changes during Abstract. Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four women receive treatment due to many factors. Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, and current professional guidelines conclude that the benefits of treatment typically outweigh the risks for healthy, symptomatic women under age 60 years and those Emerging evidence suggests that treatment with SSRIs, SNRIs, and gabapentin is effective for many women who want to avoid hormone therapy. A shared decision approach to treatment decisions involves consideration of risks with treatment options and discussion of patient priorities. Gabapentin is used to treat vasomotor symptoms (VMS) in postmenopausal women with contraindications to hormonal therapy or who prefer alternatives. We investigated the efficacy and tolerability of gabapentin for treating menopausal hot flushes via a meta-analysis. Gabapentin (Neurontin) and pregabalin (Lyrica) are anti-seizure drugs. Vasomotor symptoms (VMS) are associated with adverse health consequences and can cause signifi cant morbidity for postmenopausal women. Although hormone therapy remains the gold standard of VMS treatment in meno-pausal women, some women have contraindications to or may choose not to take hormone therapy. This article Gabapentin was found to be superior vs placebo for the relief of vasomotor symptoms, although less effective than estrogen; Evidence for pregabalin “was limited yet promising” Learn More – Primary Sources: Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |